Norelide is a luteinizing hormone-releasing hormone (LHRH) analogue used to treat advanced prostate cancer with the same efficacy as orchiectomy, and this record was analyzed to observe the efficacy and safety of the drug. LHRH analogs reduce serum testosterone concentrations by affecting the activity of the hypothalamic-pituitary-gonadal axis. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion by the pituitary gland is normally controlled by the release of LHRH from the hypothalamus, and LH stimulates testicular production of testosterone, which is quite closely related to prostate cancer, and orchiectomy has been used to treat prostate cancer with satisfactory results. LHRH analogues can mimic the effect of endo-LHRH, but the biological effect is much stronger than endogenous LHRH. After the application of LHRH analogues, serum LH can temporarily increase and testicular secretion of testosterone subsequently increases, but soon LH drops to a very low level, resulting in testicular secretion of testosterone also dropping to a very low level, thus achieving the purpose of inhibiting prostate cancer. LHRH analogues can be applied alone or in combination with anti The efficacy of LHRH analogs, which can be used alone or in combination with anti-androgens (androgen total blockade therapy), varies from report to report, with no statistical difference between the two in terms of objective remission rates, overall survival and time to progression. Norelide is an LHRH analogue, and our clinical observation shows that it can significantly reduce blood testosterone and blood PSA values, while prostate cancer shrinks or even disappears, and prostate volume is significantly reduced, with significant efficacy. According to the WHO evaluation criteria for the efficacy of solid tumors, three patients had complete disappearance of clinical symptoms, disappearance of prostate nodules on rectal examination and ultrasound, normalization of blood PSA value, no metastasis on chest X-ray and bone scan, and complete remission of prostate cancer; 27 patients had different degrees of remission of the above indicators; only one patient had no bone metastasis before medication, and two suspicious metastases appeared on bone scan after three months of medication The PSA decreased from 85.1 ng/ml to 5.7 ng/ml. norelide was able to significantly reduce the blood testosterone, the testosterone value was normal before the drug, the average 570.8?206.5Lg/L, after the drug decreased to the depot level of 50Lg/L or less, the reduction of blood testosterone is the basis of the efficacy of norelide, norelide and In contrast to orchiectomy for prostate cancer, there is no significant difference in either objective remission rate or remission time, and Norelide treatment can reduce the pain and comorbidities associated with surgery, while for hormone-insensitive cases, treatment can be stopped at any time without physical or psychological trauma, making Norelide treatment superior to orchiectomy treatment. If prostate cancer patients are already prepared for surgical debulking, they should be treated with 3 months of drug debulking first to observe the effect of debulking treatment and to be able to avoid ineffective surgical procedures in patients who are not sensitive to hormone therapy. Common side effects after the application of Norelide are hot flashes and decreased libido, which may be related to the decline of blood testosterone and too rapid hormonal changes in the body, drug-related, as creatinine is normal, so it does not affect the use of the drug, but it is important to pay attention to the changes in renal function when using the drug. Bone pain after drug use may be related to a transient increase in testosterone after drug use. Symptoms caused by increased testosterone can be alleviated by the simultaneous use of estrogen and anti-androgen. As the currently applied Norelide is a solid extended-release implant, it can release the drug continuously after injection to maintain stable blood concentration, which is superior compared with aqueous agent. The efficacy of Norelide on metastatic lesions needs further observation. The false positive rate of bone metastases diagnosed by bone scan may be as high as 30%, and MRI examination of the lesions in patients with positive findings on bone scan can confirm the diagnosis of metastatic lesions. Due to the lack of MRI scan results, and bone radiographs diagnose bone metastasis six months later than the metastasis shown by bone scan, although clinical reference to bone scan as a basis for prostate cancer staging, it is not completely confirmed as bone metastasis. 14 of the 15 cases of bone metabolism vigorous foci in this group maintained stability during the course of medication, and one case of bone metabolism vigorous foci disappeared. The effect of Norelide on bone metastases of prostate cancer lesions requires the application of more examination means and longer time observation.